exai bio
@exai.bio
cfRNA + AI for next-generation liquid biopsy (https://exai.bio)
Yesterday our co-founder and CSO @babak-a.bsky.social presented at the Biotech-Pharma Statistics Workshop (BBSW) about the powerful combination of AI and cell-free RNA to detect early-stage lung cancer in the blood.
November 7, 2025 at 5:04 PM
Yesterday our co-founder and CSO @babak-a.bsky.social presented at the Biotech-Pharma Statistics Workshop (BBSW) about the powerful combination of AI and cell-free RNA to detect early-stage lung cancer in the blood.
We’re excited to welcome Michael Nall as CEO and Board Director and new Board Directors - Steve Kafka, PhD, of S32, Dusan Perovic of Two Sigma Ventures and Emir Sandhu, MD, of Blue Venture Fund. Their leadership will be invaluable as we advance our RNA & AI liquid biopsy platform.
July 23, 2025 at 5:09 PM
We’re excited to welcome Michael Nall as CEO and Board Director and new Board Directors - Steve Kafka, PhD, of S32, Dusan Perovic of Two Sigma Ventures and Emir Sandhu, MD, of Blue Venture Fund. Their leadership will be invaluable as we advance our RNA & AI liquid biopsy platform.
Reflecting on a productive week of meetings at ASCO! Thank you to all those who visited our Innovation Hub booth to learn more about our technology. #ASCO25 #LiquidBiopsy #AI #RNA
June 6, 2025 at 6:25 PM
Reflecting on a productive week of meetings at ASCO! Thank you to all those who visited our Innovation Hub booth to learn more about our technology. #ASCO25 #LiquidBiopsy #AI #RNA
Congratulations to our Board Director Karen Knudsen MBA PhD for receiving the 2025 Allen Lichter Visionary Leader Award from American Society of Clinical Oncology (ASCO). We are so grateful for your leadership, passion and the profound impact you have on the cancer community. #ASCO25 #Leadership
June 2, 2025 at 7:58 PM
Congratulations to our Board Director Karen Knudsen MBA PhD for receiving the 2025 Allen Lichter Visionary Leader Award from American Society of Clinical Oncology (ASCO). We are so grateful for your leadership, passion and the profound impact you have on the cancer community. #ASCO25 #Leadership
💥New Publication Alert in Clinical Cancer Research💥
We are thrilled to announce our latest publication on our novel RNA and generative AI liquid biopsy platform for early colorectal cancer detection. #EarlyDetection #LiquidBiopsy #RNA
Read the full publication here: aacrjournals.org/clincancerre...
We are thrilled to announce our latest publication on our novel RNA and generative AI liquid biopsy platform for early colorectal cancer detection. #EarlyDetection #LiquidBiopsy #RNA
Read the full publication here: aacrjournals.org/clincancerre...
Detection of Early-Stage Colorectal Cancer Using Cell-Free oncRNA Biomarkers and Artificial Intelligence
Abstract. Purpose: Colorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide, and early detection significantly improves treatment outcomes, but existing blood-based tests...
aacrjournals.org
May 15, 2025 at 5:45 PM
💥New Publication Alert in Clinical Cancer Research💥
We are thrilled to announce our latest publication on our novel RNA and generative AI liquid biopsy platform for early colorectal cancer detection. #EarlyDetection #LiquidBiopsy #RNA
Read the full publication here: aacrjournals.org/clincancerre...
We are thrilled to announce our latest publication on our novel RNA and generative AI liquid biopsy platform for early colorectal cancer detection. #EarlyDetection #LiquidBiopsy #RNA
Read the full publication here: aacrjournals.org/clincancerre...
Exai Bio presented new data demonstrating the power of its RNA and AI based liquid biopsy platform to detect colorectal cancer. Stage I sensitivity in an independent cohort was 80%, exceeding other blood based approaches. Thanks to Amir Momen-Roknabadi for representing Exai Bio at #AACR25!
April 30, 2025 at 4:37 PM
Exai Bio presented new data demonstrating the power of its RNA and AI based liquid biopsy platform to detect colorectal cancer. Stage I sensitivity in an independent cohort was 80%, exceeding other blood based approaches. Thanks to Amir Momen-Roknabadi for representing Exai Bio at #AACR25!
DYK almost half of all women have dense breast tissue which means they are at higher risk of developing breast cancer? Exai is joining My Density Matters to spread awareness that today is Find Out My Breast Density Day. Talk to your doctor if you have questions. #BreastDensity #EarlyDetection
February 19, 2025 at 4:17 PM
DYK almost half of all women have dense breast tissue which means they are at higher risk of developing breast cancer? Exai is joining My Density Matters to spread awareness that today is Find Out My Breast Density Day. Talk to your doctor if you have questions. #BreastDensity #EarlyDetection
Together we unite to fight cancer and inspire hope.
#WorldCancerDay #UnitedByUnique #EarlyDetection #BreastCancer
#WorldCancerDay #UnitedByUnique #EarlyDetection #BreastCancer
February 4, 2025 at 4:56 PM
Together we unite to fight cancer and inspire hope.
#WorldCancerDay #UnitedByUnique #EarlyDetection #BreastCancer
#WorldCancerDay #UnitedByUnique #EarlyDetection #BreastCancer
Congratulations to our Board Director Karen Knudsen for receiving the 2025 Allen Lichter Visionary Leader Award from American Society of Clinical Oncology (ASCO). Your tremendous leadership and dedication continue to make a profound impact on cancer care. #ASCO25
connection.asco.org/do/asco-cong...
connection.asco.org/do/asco-cong...
ASCO Congratulates 2025 Special Awards Recipients
ASCO and Conquer Cancer will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the Society’s highest
connection.asco.org
January 29, 2025 at 7:22 PM
Congratulations to our Board Director Karen Knudsen for receiving the 2025 Allen Lichter Visionary Leader Award from American Society of Clinical Oncology (ASCO). Your tremendous leadership and dedication continue to make a profound impact on cancer care. #ASCO25
connection.asco.org/do/asco-cong...
connection.asco.org/do/asco-cong...
Our own Mehran Karimzadeh wrote a blog post about our recent Nature Communications publication demonstrating superior cancer detection performance by Exai’s AI platform compared to traditional machine learning methods. #AI #EarlyDetection #LungCancer
communities.springernature.com/posts/behind...
communities.springernature.com/posts/behind...
Behind the paper: Deep generative AI models analyzing circulating orphan non-coding RNAs enable detection of early-stage lung cancer
Our recent study in Nature Communications highlights the success of a custom generative AI framework in detecting non-small cell lung cancer and its subtypes from serum-derived orphan non-coding RNAs.
communities.springernature.com
January 28, 2025 at 5:52 PM
Our own Mehran Karimzadeh wrote a blog post about our recent Nature Communications publication demonstrating superior cancer detection performance by Exai’s AI platform compared to traditional machine learning methods. #AI #EarlyDetection #LungCancer
communities.springernature.com/posts/behind...
communities.springernature.com/posts/behind...
Today, we honor the legacy of Dr. Martin Luther King Jr., whose words continue to inspire: “The time is always right to do what is right.” At Exai, we are committed to doing what is right—advancing cancer detection and ensuring a future where everyone has access to early detection and better health.
January 20, 2025 at 5:12 PM
Today, we honor the legacy of Dr. Martin Luther King Jr., whose words continue to inspire: “The time is always right to do what is right.” At Exai, we are committed to doing what is right—advancing cancer detection and ensuring a future where everyone has access to early detection and better health.
We are honored to welcome Karen E. Knudsen, MBA, PhD, to our board of directors. As an internationally recognized oncology leader and immediate past CEO of the American Cancer Society and its advocacy affiliate ACS CAN, Karen is deeply committed to ending cancer as we know it.
December 5, 2024 at 3:49 PM
We are honored to welcome Karen E. Knudsen, MBA, PhD, to our board of directors. As an internationally recognized oncology leader and immediate past CEO of the American Cancer Society and its advocacy affiliate ACS CAN, Karen is deeply committed to ending cancer as we know it.
💥New Publication Alert in Nature Communications 💥
Our latest publication features our novel generative AI platform, showcasing superior performance in detecting lung cancer compared to traditional machine learning methods.
Read the full publication here: www.nature.com/articles/s41...
Our latest publication features our novel generative AI platform, showcasing superior performance in detecting lung cancer compared to traditional machine learning methods.
Read the full publication here: www.nature.com/articles/s41...
Deep generative AI models analyzing circulating orphan non-coding RNAs enable detection of early-stage lung cancer
Nature Communications - A generative AI model, Orion, learns a robust and generalizable pattern of non-small cell lung cancer from cancer-specific circulating non-coding RNAs. Orion enhances the...
www.nature.com
November 21, 2024 at 11:54 PM
💥New Publication Alert in Nature Communications 💥
Our latest publication features our novel generative AI platform, showcasing superior performance in detecting lung cancer compared to traditional machine learning methods.
Read the full publication here: www.nature.com/articles/s41...
Our latest publication features our novel generative AI platform, showcasing superior performance in detecting lung cancer compared to traditional machine learning methods.
Read the full publication here: www.nature.com/articles/s41...
Exai was proud to be part of the inaugural RISE UP For Breast Cancer Meeting hosted by UCSF. #breastcancer #womenshealth #UCSF
November 8, 2024 at 7:59 PM
Exai was proud to be part of the inaugural RISE UP For Breast Cancer Meeting hosted by UCSF. #breastcancer #womenshealth #UCSF
3 years of innovation never looked so sweet! Celebrating Exai’s 3rd anniversary today, one donut (and breakthrough) at a time! #lifeatexai
September 23, 2024 at 4:44 PM
3 years of innovation never looked so sweet! Celebrating Exai’s 3rd anniversary today, one donut (and breakthrough) at a time! #lifeatexai
Exai was proud to attend #ESMO2024, where we announced new data demonstrating the ability of our RNA liquid biopsy platform to determine breast cancer tumor ER and HER2 status. #liquidbiopsy #breastcancer
September 19, 2024 at 1:46 PM
Exai was proud to attend #ESMO2024, where we announced new data demonstrating the ability of our RNA liquid biopsy platform to determine breast cancer tumor ER and HER2 status. #liquidbiopsy #breastcancer
Join us at #ESMO2024 where Exai will present new data demonstrating the ability of our RNA liquid biopsy platform to determine breast cancer tumor ER and HER2 status. #liquidbiopsy #breastcancer
September 13, 2024 at 2:46 PM
Join us at #ESMO2024 where Exai will present new data demonstrating the ability of our RNA liquid biopsy platform to determine breast cancer tumor ER and HER2 status. #liquidbiopsy #breastcancer
We’re excited to announce Dave Daly has been appointed as Exai Bio’s CEO. Dave brings more than 30 years of extensive cancer diagnostics and executive leadership experience to lead the next chapter of Exai.
www.exai.bio/news/exai-bi...
www.exai.bio/news/exai-bi...
July 24, 2024 at 4:30 PM
We’re excited to announce Dave Daly has been appointed as Exai Bio’s CEO. Dave brings more than 30 years of extensive cancer diagnostics and executive leadership experience to lead the next chapter of Exai.
www.exai.bio/news/exai-bi...
www.exai.bio/news/exai-bi...
Exai celebrates diversity and wishes everyone a very happy Pride Month. #PrideMonth #earlydetection #lifeatexai #MRD
June 19, 2024 at 4:07 PM
Exai celebrates diversity and wishes everyone a very happy Pride Month. #PrideMonth #earlydetection #lifeatexai #MRD
Proud to present our latest RNA- and AI-based #liquidbiopsy research at #ASCO24! #earlydetection #lifeatexai #MRD
June 4, 2024 at 5:22 PM
Proud to present our latest RNA- and AI-based #liquidbiopsy research at #ASCO24! #earlydetection #lifeatexai #MRD
May 28, 2024 at 5:50 PM
Exai co-founder, Hani Goodarzi, in collaboration with Dr. Laura Essserman and Dr. Laura van ‘t Veer from UCSF, posted a preprint, which provides the history of oncRNAs and their power to predict clinical outcomes and monitor disease burden based on the I-SPY 2 Trial. www.biorxiv.org/content/10.1...
April 22, 2024 at 4:59 PM
Exai co-founder, Hani Goodarzi, in collaboration with Dr. Laura Essserman and Dr. Laura van ‘t Veer from UCSF, posted a preprint, which provides the history of oncRNAs and their power to predict clinical outcomes and monitor disease burden based on the I-SPY 2 Trial. www.biorxiv.org/content/10.1...
The Exai team had a productive week at #AACR24! We were proud to showcase our #liquidbiopsy research in both early cancer detection and MRD. #earlydetection #lifeatexai #MRD
April 15, 2024 at 5:50 PM
The Exai team had a productive week at #AACR24! We were proud to showcase our #liquidbiopsy research in both early cancer detection and MRD. #earlydetection #lifeatexai #MRD